Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent as documented by signature~* World Health Organization (WHO) performance status≤ 2~* Body weight ≤ 80 kg~* Biopsy proven invasive breast cancer with a size of ≤3.0cm (TNM classification: cT1-2 N0-2 MX ).~* Histological type of tumor: invasive ductal carcinoma (IDC)~* Patient is scheduled for surgical resection of tumor at study site~* Tumor location within the reach of the HIFU transducers with the patient in prone position; distance from skin and pectoral muscle to the tumor ≥ 1.0 cm.~* Target breast fits in the cup of the dedicated MR-HIFU breast system~Exclusion Criteria:~* neoadjuvant systemic therapy~* prior radiotherapy in target breast~* contraindications for MRI~* contraindication for application of gadolinium-based contrast agent~* contraindication for procedural sedation analgesia~* macro-calcifications in or around the targeted tumor~* scar tissue or surgical clips in the direct path of the ultrasound beams~* Women who are pregnant or breast feeding,~* Intention to become pregnant during the course of the study,~* Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.~* Known or suspected non-compliance, drug or alcohol abuse,~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,~* Participation in another study with investigational drug/device within the 30 days preceding and during the present study,~* Previous enrolment into the current study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MR-HIFU treatment (Type: EXPERIMENTAL): Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat\& resect model

Based on this trial design, predict the completion outcome and termination type (if applicable).